USPTO issues Certificate of Registration for Echo's SYMPHONY and PRELUDE trademarks

Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Trademark Office for its SYMPHONY and PRELUDE trademarks, as used with Echo's tCGM system and mechanical skin ablator, respectively.  The Certificate of Registration for the SYMPHONY trademark was issued on August 2, 2011, and for the PRELUDE trademark on July 26, 2011.

The registration gives Echo exclusive nationwide rights to use the SYMPHONY and PRELUDE trademarks on or in connection with the associated products, potentially in perpetuity.

"We are pleased to receive these registered trademarks in connection with our Symphony tCGM System and Prelude SkinPrep System.  They are valuable pieces of intellectual property for Echo as we continue to grow and protect our brands," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "This achievement marks another important step in the commercialization of Symphony and Prelude."